- Home
- XXII vs VBIO Comparison
XXII vs VBIO Comparison
Compare XXII & VBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XXII | VBIO |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5M | 1.6M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | XXII | VBIO |
|---|---|---|
| Price | $4.40 | $0.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.9K | ★ 817.9K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.96 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,832,530.00 | $780,000.00 |
| Revenue This Year | $370.28 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.27 | $0.25 |
| 52 Week High | $11.37 | $0.61 |
Technical Indicators
Market Signals| Indicator | XXII | VBIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.32 | 36.28 |
| Support Level | $3.65 | $0.26 |
| Resistance Level | $4.64 | $0.37 |
| Average True Range (ATR) | 0.27 | 0.06 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 55.15 | 21.91 |
Price Performance
Historical ComparisonAbout XXII 22nd Century Group Inc.
22nd Century Group Inc is a tobacco products company that enables cigarette smokers to take control of their consumption of nicotine, the addictive drug in cigarettes. The company manufactures and distributes the only combustible tobacco products containing minimally or non-addictive levels of nicotine. The Company has organized its business as a single reportable segment: tobacco, as it operates and derives all revenues from its tobacco operations and products.
About VBIO Valion Bio Inc. Common Stock
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.